Control

CuriRx Launches CuriLytics™ Platform to Provide CMC Analytical Services to Support Complex Biotherapeutic Development Using High Resolution Mass Spectrometry

Tuesday, September 21, 2021 - 1:49pm

Led by CuriRx's team of industry experts and state-of-the-art high-resolution Orbitrap mass spectrometry instrumentation, the CuriLytics platform provides support to developers of complex biotherapeutics.

Key Points: 
  • Led by CuriRx's team of industry experts and state-of-the-art high-resolution Orbitrap mass spectrometry instrumentation, the CuriLytics platform provides support to developers of complex biotherapeutics.
  • Improving and de-risking the overall drug development path from Phase I clinical trials through approval requires advanced analyses of critical quality attributes.
  • The CuriLytics platform is designed to provide confidence to biotherapeutic developers from discovery to regulatory approval."
  • CuriRx is planning to hold a webinar on "De-risking product development by using high-resolution mass spectrometry for proteomic characterization" in October, 2021.

CERTIFY Health Partners With Elo to Improve Patient Check-in & Satisfaction

Tuesday, September 21, 2021 - 1:00pm

GAITHERSBURG, Md.and MILPITAS, Calif., Sept. 21, 2021 /PRNewswire/ -- CERTIFY Health and Elo, CERTIFY's preferred touchscreen vendor, are announcing their partnership to offer a patient self-service solution.

Key Points: 
  • GAITHERSBURG, Md.and MILPITAS, Calif., Sept. 21, 2021 /PRNewswire/ -- CERTIFY Health and Elo, CERTIFY's preferred touchscreen vendor, are announcing their partnership to offer a patient self-service solution.
  • Through integrating Elo's All-in-One touchscreen computers with CERTIFY Care's cloud-based interface, healthcare providers and institutions can optimize patient check-in workflows.
  • With this solution, enterprises can automate patient intake workflows to replace the traditional check-in procedures and improve patient experience.
  • CERTIFY and Elo will continue to expand this partnership to provide healthcare organizations with the tools they need to guarantee patient satisfaction.

Verrica Pharmaceuticals Receives Complete Response Letter from the FDA identifying deficiencies at a facility of a Contract Manufacturer for its New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

Monday, September 20, 2021 - 9:05pm

WEST CHESTER, Pa., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum). The Company had previously disclosed that the FDA extended the Prescription Drug User Fee Act (PDUFA) goal date for the NDA by three months to September 23, 2021 to allow the Agency additional time to review information submitted by the Company in response to comments from the Agency regarding the Company’s human factors study.

Key Points: 
  • More importantly, the FDA did not identify any clinical, safety or product specific Chemistry, Manufacturing, and Controls (CMC) deficiencies related to VP-102.
  • Molluscum is a highly contagious viral skin disease that affects approximately six million people primarily children in the United States.
  • Without treatment, molluscum can last for an average of 13 months, and in some cases, up to several years.
  • A Complete Response Letter was received from the FDA regarding the NDA for VP-102 onSeptember 17, 2021.

CDC and Bark Technologies Collaborate on First-Ever Study Linking Past Online Behavior in Youth to Future Events of Suicide and Self-Harm

Monday, September 20, 2021 - 4:06pm

Over the past decade and specifically throughout the pandemic increased online communication has proliferated concerning behaviors among young people, including suicide and self-harm.

Key Points: 
  • Over the past decade and specifically throughout the pandemic increased online communication has proliferated concerning behaviors among young people, including suicide and self-harm.
  • The CDC/Bark study analyzed online activities of middle and high school-aged children sampled over a 13-month period.
  • The data used in the study were from Bark's ongoing programs to provide safety monitoring in schools and as part of efforts to improve suicide prevention.
  • "We are honored to collaborate on this critical research and partner with the CDC to preserve and protect youth mental health," said Brian Bason, Bark founder and CEO.

Artec 3D Launches Artec Studio 16 Featuring Artec Cloud, Enabling Collaboration from Anywhere

Monday, September 20, 2021 - 2:00pm

Our development of industry-leading software solutions and AI-powered algorithms is critical for enabling the 3D scanning industry to reach new heights.

Key Points: 
  • Our development of industry-leading software solutions and AI-powered algorithms is critical for enabling the 3D scanning industry to reach new heights.
  • The release of Artec Studio 16 and Artec Cloud equips users with unprecedented collaboration opportunities, flexible workflows, faster 3D data processing, and numerous feature-rich tools to meet any need.
  • An uninterrupted scan-to-inspection workflow allows users to finish a scan, inspect a mesh, or run inspection in CX from Artec Studio.
  • Artec has a team of professional experts in the collection and processing of 3D surfaces as well as biometric facial recognition.

Viasat Awarded Two Department of Defense Research Contracts to Help U.S. Warfighters Harness 5G Connectivity on the Battlespace

Monday, September 20, 2021 - 1:00pm

These awards are part of the DoD $600M 5G research initiative announced last year, to explore how 5G technology can strengthen warfighting capabilities.

Key Points: 
  • These awards are part of the DoD $600M 5G research initiative announced last year, to explore how 5G technology can strengthen warfighting capabilities.
  • Viasat is working with the DoD to solve complex communications problems across multiple network domainsfrom satellite to cellular to government specific networking waveforms.
  • Viasat will also explore how 5G connectivity can support bandwidth-intensive applications (e.g.
  • ISR mapping), be leveraged to share real-time situational awareness information and be used to provide resilient cloud access to the battlefield.

DGAP-News: DEFENCE THERAPEUTICS SUCCESSFULLY ENGINEERED AND TESTED A NOVEL INTRANASAL COVID-19 VACCINE FORMULATION IN ANIMALS

Monday, September 20, 2021 - 8:00am

Vancouver, BC, Canada, September 20th, 2021 - Defence Therapeutics Inc. ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines is pleased to announce the development of a "non-injectable" second generation COVID vaccine, AccuVAC-IN002, for intranasal delivery.

Key Points: 
  • Vancouver, BC, Canada, September 20th, 2021 - Defence Therapeutics Inc. ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines is pleased to announce the development of a "non-injectable" second generation COVID vaccine, AccuVAC-IN002, for intranasal delivery.
  • Defence is therefore dedicated to fight this airborne disease and any other emerging pathogens through its vaccine development program.
  • Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform.
  • The core of Defence Therapeutics platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells.

Datopotamab Deruxtecan Shows Encouraging Tumor Response in Patients with Advanced Non-Small Cell Lung Cancer with Actionable Genomic Alterations

Sunday, September 19, 2021 - 4:30pm

The dose escalation part of the study assessed the safety and tolerability of increasing doses of datopotamab deruxtecan to determine the maximum tolerated dose and/or recommended dose for expansion in patients with unresectable advanced NSCLC.

Key Points: 
  • The dose escalation part of the study assessed the safety and tolerability of increasing doses of datopotamab deruxtecan to determine the maximum tolerated dose and/or recommended dose for expansion in patients with unresectable advanced NSCLC.
  • The dose expansion part of the study further assessed the safety and tolerability of datopotamab deruxtecan at selected dose levels (4 mg/kg, 6 mg/kg and 8 mg/kg) in patients with NSCLC.
  • Efficacy endpoints include ORR, disease control rate, DOR, time to response, progression-free survival and overall survival.
  • Daiichi Sankyo and AstraZeneca entered into a global collaboration to jointly develop and commercialize datopotamab deruxtecan in July 2020 , except in Japan where Daiichi Sankyo maintains exclusive rights.

A $153 Billion Global Opportunity for Industrial Controls by 2026 - New Research from StrategyR

Friday, September 17, 2021 - 4:06pm

SAN FRANCISCO, Sept. 17, 2021 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Industrial Controls - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, Sept. 17, 2021 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Industrial Controls - Global Market Trajectory & Analytics" .
  • Preview Registry
    Amid the COVID-19 crisis, the global market for Industrial Controls estimated at US$123.4 Billion in the year 2020, is projected to reach a revised size of US$153 Billion by 2026, growing at a CAGR of 3.6% over the analysis period.
  • The U.S. Market is Estimated at $34.3 Billion in 2021, While China is Forecast to Reach $31.4 Billion by 2026
    The Industrial Controls market in the U.S. is estimated at US$34.3 Billion in the year 2021.
  • Global Industry Analysts, Inc., ( www.strategyr.com ) is a renowned market research publisher the world`s only influencer driven market research company.

Elucida Oncology Announces First Patient Dosed in Phase 1/2 Study of ELU001 in Patients with Advanced, Recurrent, or Refractory Cancers Overexpressing Folate-Receptor Alpha (FRα)

Friday, September 17, 2021 - 3:15pm

ELU001 is Elucida Oncologys lead CDC therapeutic candidate designed to enhance efficacy and reduce off-target toxicity in the treatment of patients with FRa expressing tumors.

Key Points: 
  • ELU001 is Elucida Oncologys lead CDC therapeutic candidate designed to enhance efficacy and reduce off-target toxicity in the treatment of patients with FRa expressing tumors.
  • In pre-clinical studies, ELU001 outperformed an anti-FR ADC across multiple cancer models expressing lower copy numbers of FR.
  • We look forward to advancing ELU001 and additional CDCs that have the potential to offer more effective and better tolerated therapies for patients with cancer.
  • Elucida Oncology, Inc., is a biotechnology company pioneering the next frontier in targeted cancer therapy with its first-in-class, ultra-small nanoparticle CDot drug delivery platform.